Oligonucleotide inhibition of epidermal growth factor receptor expression
AssigneesIsis Pharmaceuticals, Inc., The Penn State Research Foundation
InventorsC. Frank Bennett, Allan Lipton, Lois M. Witters
Life of this patent
Estimating the term…
Abstract
Compounds, compositions and methods are provided for inhibiting the expression of human EGFR. The compositions comprise oligonucleotides complementary to mRNA targeted to nucleic acids encoding EGFR. Methods of using these oligonucleotides for inhibition of EGFR expression and for treatment of diseases such as cancers associated with overexpression of EGFR are provided.
Claims23
An oligonucleotide 12-25 nucleotides in length comprising a nucleotide sequence complementary to the 5′ untranslated region or coding region of a nucleic acid molecule encoding a human epidermal growth factor receptor, wherein said oligonucleotide inhibits the expression of said human epidermal growth factor receptor.
An oligonucleotide 12-25 nucleorides in length comprising at least one base modification or 2′-modification and comprising a nucleotide sequence complementary to the 5′ untranslated region, or coding region of a nucleic acid molecule encoding a human epidermal growth factor receptor, wherein said oligonucleotide inhibits the expression of said human epidermal growth factor receptor.
A method of modulating the expression of a human epidermal growth factor receptor in cells or tissues in vitro or ex vivo comprising contacting said cells or tissues with an oligonucleotide 12-25 nucleotides in length comprising at least one base modification or 2′-modification and comprising a nucleotide sequence complimentary to the 5′ untranslated region or coding region of a nucleic acid molecule encoding a human epidermal growth factor receptor.
Dependencies are inferred from the claim text.